<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000258252"><TermName>Gleevec</TermName><TermPronunciation>(GLEE-vek)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat different types of leukemia and other cancers of the blood, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a rare condition called systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Gleevec blocks the protein made by the bcr/abl oncogene. It is a type of tyrosine kinase inhibitor. Also called imatinib mesylate and STI571.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000710086" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Gleevec&quot;" language="en" id="_3"/><MediaLink ref="CDR0000710085" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Gleevec&quot;" language="es" id="_4"/><SpanishTermName>Gleevec</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para tratar diferentes tipos de leucemia y otros cánceres de la sangre, tumores del estroma gastrointestinal, tumores de la piel llamados dermatofibrosarcomas protuberantes y una afección poco frecuente llamada mastocitosis sistémica. También está en estudio para el tratamiento de otros tipos de cáncer. Gleevec bloquea la proteína que produce el oncogén bcr/abl. Es un tipo de inhibidor de la tirosina cinasa. También se llama mesilato de imatinib y STI571.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2002-10-19</DateFirstPublished><DateLastModified>2007-06-05</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000487488">Imatinib Mesylate</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
